[1]
|
Yamana, H., Imai, S., Yamasaki, K., et al. (2021) Prognosis of Patients with Liver Cirrhosis: A Multi-Center Retrospec-tive Observational Study. Hepatology Research, 51, 1196-1206. https://doi.org/10.1111/hepr.13711
|
[2]
|
Mokdad, A.A., Lopez, A.D., Shahraz, S., et al. (2014) Liver Cirrhosis Mortality in 187 Countries between 1980 and 2010: A Systematic Analysis. BMC Medicine, 12, Article No. 145. https://doi.org/10.1186/s12916-014-0145-y
|
[3]
|
左罗. 经颈静脉肝内门体分流术治疗肝硬化生存获益及危险因素的回顾性研究[D]: [博士学位论文]. 西安: 中国人民解放军空军军医大学, 2020.
|
[4]
|
中华医学会消化病学分会消化介入学组. 经颈静脉肝内门体静脉分流术治疗肝硬化门静脉高压共识意见[J]. 临床肝胆病杂志, 2014, 30(3): 210-213.
|
[5]
|
中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2022年版)[J]. 中华肝脏病杂志, 2022, 30(12): 1332-1348.
|
[6]
|
中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 酒精性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34(5): 939-946.
|
[7]
|
中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华肝脏病杂志, 2022, 30(12): 1309-1331.
|
[8]
|
陆伦根, 蔡晓波, 王建设, 等. 胆汁淤积性肝病管理指南(2021)[J]. 临床肝胆病杂志, 2022, 38(1): 62-69.
|
[9]
|
Nilsson, E., Anderson, H., Sar-genti, K., Lindgren, S. and Prytz, H. (2019) Clinical Course and Mortality by Etiology of Liver Cirrhosis in Sweden: A Population Based, Long-Term Follow-Up Study of 1317 Patients. Alimentary Pharmacology & Therapeutics, 49, 1421-1430. https://doi.org/10.1111/apt.15255
|
[10]
|
Horhat, A., Bureau, C., Thabut, D. and Rudler, M. (2021) Transjugular Intrahepatic Portosystemic Shunt in Patients with Cirrhosis: Indications and Posttransjugular Intrahepatic Portosystemic Shunt Complications in 2020. United European Gastroenterology Journal, 9, 203-208. https://doi.org/10.1177/2050640620952637
|
[11]
|
Hayashi, H., Beppu, T., Shirabe, K., Maehara, Y. and Baba, H. (2014) Management of Thrombocytopenia Due to Liver Cirrhosis: A Review. World Journal of Gastroenterology, 20, 2595-2605. https://doi.org/10.3748/wjg.v20.i10.2595
|
[12]
|
Ali, R.O., Moon, M.S., Townsend, E.C., et al. (2020) Exploring the Link between Platelet Numbers and Vascular Homeostasis Across Early and Late Stages of Fibrosis in Hepatitis C. Digestive Diseases and Sciences, 65, 524-533.
https://doi.org/10.1007/s10620-019-05760-x
|
[13]
|
Doi, T., Homma, H., Mezawa, S., et al. (2002) Mechanisms for Increment of Platelet Associated IgG and Platelet Surface IgG and Their Implications in Immune Thrombocytopenia As-sociated with Chronic Viral Liver Disease. Hepatology Research, 24, 22-23. https://doi.org/10.1016/S1386-6346(02)00010-4
|
[14]
|
Sanjo, A., Satoi, J., Ohnishi, A., Maruno, J., Fukata, M. and Suzuki, N. (2003) Role of Elevated Platelet-Associated Immunoglobulin G and Hypersplenism in Thrombocytopenia of Chronic Liver Diseases. Journal of Gastroenterology and Hepatology, 18, 638-644. https://doi.org/10.1046/j.1440-1746.2003.03026.x
|
[15]
|
Feistauer, S.M., Penner, E., Mayr, W.R. and Panzer, S. (1997) Target Platelet Antigens of Autoantibodies in Patients with Primary Biliary Cirrhosis. Hepatology, 25, 1343-1345. https://doi.org/10.1002/hep.510250607
|
[16]
|
Alhendi, F. (2023) A Patient with Alcoholic Liver Disease Reports for Treatment of Dentoalveolar Abscess in Relation to Maxillary Left Molar. Dental Clinics of North America, 67, 549-552. https://doi.org/10.1016/j.cden.2023.02.042
|
[17]
|
Davila, J.A., Morgan, R.O., Shaib, Y., McGlynn, K.A. and El-Serag, H.B. (2005) Diabetes Increases the Risk of Hepatocellular Carcinoma in the United States: A Population Based Case Control Study. Gut, 54, 533-539.
https://doi.org/10.1136/gut.2004.052167
|
[18]
|
Bengtsson, B., Widman, L., Wahlin, S., Stal, P., Björkström, N.K. and Hagström, H. (2022) The Risk of Hepatocellular Carcinoma in Cirrhosis Differs by Etiology, Age and Sex: A Swe-dish Nationwide Population-Based Cohort Study. United European Gastroenterology Journal, 10, 465-476. https://doi.org/10.1002/ueg2.12238
|
[19]
|
Sharma, S.A., Kowgier, M., Hansen, B.E., et al. (2017) Toronto HCC Risk Index: A Validated Scoring System to Predict 10-Year Risk of HCC in Patients with Cirrhosis. Journal of Hepa-tology, 68, 92-99.
https://doi.org/10.1016/j.jhep.2017.07.033
|
[20]
|
Bhala, N., Angulo, P., Van Der Poorten, D., et al. (2011) The Nat-ural History of Nonalcoholic Fatty Liver Disease with Advanced Fibrosis or Cirrhosis: An International Collaborative Study. Hepatology, 54, 1208-1216.
https://doi.org/10.1002/hep.24491
|
[21]
|
Tripathi, D., Stanley, A.J., Hayes, P.C., et al. (2020) Transjugular Intrahe-patic Portosystemic Stent-Shunt in the Management of Portal Hypertension. Gut, 69, 1173-1192. https://doi.org/10.1136/gutjnl-2019-320221
|
[22]
|
Patel, R.K., Chandel, K., Tripathy, T.P. and Mukund, A. (2021) Complications of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in the Era of the Stent Graft—What the Interven-tionists Need to Know? European Journal of Radiology, 144, Article 109986. https://doi.org/10.1016/j.ejrad.2021.109986
|
[23]
|
Lopera, J.E. (2023) A Comprehensive Review of Transjugular In-trahepatic Portosystemic Shunt-Related Complications. Seminars in Interventional Radiology, 40, 55-72. https://doi.org/10.1055/s-0043-1767670
|
[24]
|
Casadaban, L.C., Parvinian, A., Couture, P.M., et al. (2014) Charac-terization of Liver Function Parameter Alterations after Transjugular Intrahepatic Portosystemic Shunt Creation and As-sociation with Early Mortality. American Journal of Roentgenology, 203, 1363-1370. https://doi.org/10.2214/AJR.13.12232
|